{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:24:21Z","timestamp":1761488661321,"version":"3.44.0"},"reference-count":53,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2011,3,7]]},"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>The efficacy of anti-tumour necrosis factor (anti-TNF\u03b1) therapy with infliximab and adalimumab in moderate to severe Crohn's disease has now been proved. This article reviews the evidence supporting best practice with these agents in the light of recent National Institute for Health and Clinical Excellence guidance. Recent studies point to greater efficacy when these drugs are used early in the disease, particularly when mucosal healing can be achieved. For infliximab, the combination with immunomodulator drugs appears to afford greater efficacy, but possibly at the expense of the risk of rare but serious side effects. Patients should be selected carefully for treatment based on prognostic factors predicting aggressive disease, on the one hand, and comorbid factors that might predict side effects, on the other. Multiple drug combinations should be avoided where possible. Finally, a minority of patients in stable remission with complete mucosal healing may be selected for anti-TNF\u03b1 drug withdrawal.<\/jats:p>","DOI":"10.1136\/fg.2010.003566","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T21:59:30Z","timestamp":1301954370000},"page":"144-150","source":"Crossref","is-referenced-by-count":4,"title":["Evidence-based use of anti-TNF\u03b1 therapy in Crohn's disease; where are we in 2011?"],"prefix":"10.1136","volume":"2","author":[{"given":"S M","family":"Everett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P J","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2011,4,4]]},"reference":[{"unstructured":"National Institute for Health and Clinical Excellence. Crohn's Disease \u00e2\u0080\u0093 Infliximab (Review) and Adalimumab (Review of TA40): guidance. London: NICE, 2010. http:\/\/www.nice.org.uk\/guidance\/TA187 (accessed 29 March 2011).","key":"2025090708340267000_2.3.144.1"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.2","DOI":"10.1056\/NEJM199710093371502"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.3","DOI":"10.1053\/j.gastro.2005.11.030"},{"doi-asserted-by":"crossref","unstructured":"Behm BW Bickston SJ . Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893.","key":"2025090708340267000_2.3.144.4","DOI":"10.1002\/14651858.CD006893"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.5","DOI":"10.1136\/gut.2008.155812"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.6","DOI":"10.1053\/j.gastro.2003.11.014"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.7","DOI":"10.1053\/j.gastro.2008.07.069"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.8","DOI":"10.1053\/j.gastro.2009.09.056"},{"unstructured":"Schnitzler F . Why should we aim to achieve mucosal healing. In: Mucosal Healing: Following the Right Track in Crohn's Disease. London: BMJ Group 2010:7\u00e2\u0080\u00939.","key":"2025090708340267000_2.3.144.9"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.10","DOI":"10.1097\/00054725-200207000-00002"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.11","DOI":"10.1136\/gut.49.6.777"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.12","DOI":"10.1016\/j.cgh.2007.09.002"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.13","DOI":"10.1053\/j.gastro.2005.12.019"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.14","DOI":"10.1080\/00365520801957149"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.15","DOI":"10.1136\/gut.2005.084061"},{"key":"2025090708340267000_2.3.144.16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","article-title":"Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease","volume":"104","author":"Romberg-Camps","year":"2009","journal-title":"Am J Gastroenterol"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.17","DOI":"10.1136\/gut.52.4.552"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.18","DOI":"10.1053\/j.gastro.2008.06.081"},{"key":"2025090708340267000_2.3.144.19","first-page":"947","article-title":"Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy","volume":"97","author":"Allez","year":"2002","journal-title":"Am J Gastroenterol"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.20","DOI":"10.1016\/j.cgh.2006.03.002"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.21","DOI":"10.1053\/j.gastro.2006.02.014"},{"doi-asserted-by":"crossref","unstructured":"Costes L Colombel JF Mary J . P010 long term follow-up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008;134 (Suppl 1):A-134.","key":"2025090708340267000_2.3.144.22","DOI":"10.1016\/S0016-5085(08)60621-6"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.23","DOI":"10.1016\/S0140-6736(08)60304-9"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.24","DOI":"10.1056\/NEJMoa0904492"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.25","DOI":"10.1046\/j.1365-2036.2003.01574.x"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.26","DOI":"10.1111\/j.1572-0241.2002.05991.x"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.27","DOI":"10.1056\/NEJMoa020888"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.28","DOI":"10.1136\/gut.2006.099978"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.29","DOI":"10.1053\/j.gastro.2008.01.012"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.30","DOI":"10.1136\/gut.2008.163279"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.31","DOI":"10.1136\/gut.2006.115980"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.32","DOI":"10.1111\/j.1365-2036.2009.04027.x"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.33","DOI":"10.1053\/j.gastro.2006.11.041"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.34","DOI":"10.1053\/j.gastro.2008.03.004"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.35","DOI":"10.1136\/gut.2010.212712"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.36","DOI":"10.1016\/S0140-6736(02)08512-4"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.37","DOI":"10.1038\/ajg.2008.88"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.38","DOI":"10.1002\/art.10302"},{"key":"2025090708340267000_2.3.144.39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MEG.0b013e32832b20d4","article-title":"Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland","volume":"22","author":"Russo","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.40","DOI":"10.1136\/gut.2006.106781"},{"key":"2025090708340267000_2.3.144.41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2036.2009.04101.x","article-title":"Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"30","author":"Ma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090708340267000_2.3.144.42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","article-title":"The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy","volume":"32","author":"Lichtiger","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.43","DOI":"10.1053\/j.gastro.2003.10.047"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.44","DOI":"10.1136\/gut.2008.163642"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.45","DOI":"10.1111\/j.1365-2036.2008.03882.x"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.46","DOI":"10.1136\/gut.2003.018515"},{"key":"2025090708340267000_2.3.144.47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2036.2009.04206.x","article-title":"Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice","volume":"31","author":"Zabana","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.48","DOI":"10.1038\/ajg.2009.322"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.49","DOI":"10.1136\/gut.2005.075937"},{"key":"2025090708340267000_2.3.144.50","first-page":"A178","article-title":"Safety of infliximab and other Crohn's disease therapies \u00e2\u0080\u0093 TREAT registry data with nearly 20,000 patient-years of follow up","volume":"132","author":"Lichtenstein","year":"2007","journal-title":"Gastroenterology"},{"doi-asserted-by":"publisher","key":"2025090708340267000_2.3.144.51","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"2025090708340267000_2.3.144.52","first-page":"A466","article-title":"The course of infliximab discontinuation after long-term maintenance therapy in Crohn's disease","volume":"58","author":"Armuzzi","year":"2009","journal-title":"Gut"},{"key":"2025090708340267000_2.3.144.53","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(09)60659-4","article-title":"Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study","volume":"136","author":"Louis","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/fg.2010.003566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:34:10Z","timestamp":1757259250000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/fg.2010.003566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,4]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,5,27]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1136\/fg.2010.003566"],"URL":"https:\/\/doi.org\/10.1136\/fg.2010.003566","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"type":"print","value":"2041-4137"},{"type":"electronic","value":"2041-4145"}],"subject":[],"published":{"date-parts":[[2011,4,4]]}}}